hyperthyroidism
Split thyrotoxicosis into high radioactive iodine uptake (RAIU) (overproduction: Graves, TMNG, toxic adenoma — treat with antithyroid drugs, RAI, or surgery) vs low RAIU (destructive release or exogenous hormone — antithyroid drugs do not work). Ophthalmopathy = Graves disease regardless of RAIU. First-line antithyroid drug is methimazole (except first trimester of pregnancy and thyroid storm → PTU).
Thyroid storm (fever, delirium/agitation, tachycardia/AF, HF, GI/jaundice) is a clinical diagnosis requiring immediate ICU management before confirmatory labs → thyroid emergencies. Any patient on antithyroid drugs with fever or sore throat needs an urgent CBC for agranulocytosis (ANC <0.5 × 10⁹/L) and immediate drug cessation.
diagnostic approach — high vs low RAIU
Confirm suppressed TSH with elevated free T4 and/or free T3 (T3-toxicosis occurs early in Graves and toxic nodules). Biotin (>30 µg/day; often 5–10 mg OTC for hair/nails) interferes with streptavidin-biotin immunoassays → falsely low TSH and falsely high free T4/T3 mimicking Graves; hold biotin ≥72 hours before retesting.
- Clinical Graves (diffuse goitre + orbitopathy or pretibial myxoedema) or positive TRAb: no RAIU needed — diagnosis is established.
- Uncertain aetiology: order TRAb or ¹²³I uptake and scan (RAIU) (never in pregnancy/breastfeeding; colour-flow Doppler US is an alternative).
| RAIU pattern | causes | key distinguishing features |
|---|---|---|
| high / normal — diffuse | Graves disease | TRAb+, diffuse bruit/goitre, orbitopathy, dermopathy |
| high / normal — patchy / focal | TMNG (patchy) · toxic adenoma (single hot nodule, suppressed remainder) | older adults, no orbitopathy; do not FNA a hot nodule |
| low (<5%) | subacute (de Quervain) thyroiditis | painful tender thyroid, ↑ ESR/CRP, post-viral |
| low (<5%) | painless / postpartum / ICI thyroiditis | painless; triphasic (hyper → hypo → recovery); ICI often progresses to permanent hypothyroidism |
| low (<5%) | amiodarone-induced (AIT) | Type 1 (iodine-induced synthesis) vs Type 2 (destructive); RAIU often falsely low in both |
| low (<5%) | factitious / exogenous · struma ovarii | exogenous → low/undetectable thyroglobulin; struma ovarii → high thyroglobulin + pelvic uptake |
- Falsely low RAIU: recent iodinated CT contrast, amiodarone, kelp/iodine supplements, or active thionamide use. Ophthalmopathy still confirms Graves even if RAIU is suppressed.
symptom control and definitive management
- β-blockers for all symptomatic patients (especially older adults, resting HR >90 bpm, or CVD): propranolol (also inhibits T4 → T3 conversion at high doses), atenolol, or metoprolol.
- Subclinical hyperthyroidism (low TSH, normal free T4/T3): treat if TSH <0.1 mU/L and age ≥65, osteoporosis, heart disease/atrial fibrillation, or symptoms (consider if TSH 0.1–0.4 with same risks).
Graves disease — three options
| modality | role & timing | key contraindications / caveats |
|---|---|---|
| antithyroid drugs (methimazole first-line) | 12–18 months; ~50% remission (higher if small goitre, falling TRAb); takes 4–6 weeks for full effect | PTU only for T1 pregnancy, thyroid storm, or minor MMZ intolerance. Major reaction (agranulocytosis, transaminases >3× ULN, ANCA vasculitis) → stop permanently, never switch |
| radioactive iodine (¹³¹I) | single oral ablative dose; definitive hypothyroidism in >80% (lifelong LT4) | contraindicated in pregnancy, breastfeeding, moderate–severe active orbitopathy, or suspected thyroid cancer. Delay pregnancy 6 months. Hold methimazole 2–3 days before RAI. Cover mild active GO with oral prednisone |
| total thyroidectomy | rapid definitive cure (large compressive goitre, coexisting cancer, severe GO, pregnancy refractory to ATDs, desire for pregnancy <6 months) | render euthyroid first; give SSKI or Lugol’s iodine × 10 days pre-op (↓ vascularity/blood loss); watch for hypoparathyroidism and RLN injury |
TMNG and toxic adenoma
- Do not remit spontaneously → definitive RAI or surgery (surgery preferred for compressive goitre, suspected malignancy, or rapid control; lifelong low-dose methimazole is an option in frail older adults).
thyroiditis (low-RAIU)
- Thionamides are ineffective (preformed hormone leak, no excess synthesis). Treat symptoms with β-blockers.
- Subacute (painful): NSAIDs first-line; prednisone if severe pain or refractory.
- ICI-induced thyroiditis: β-blocker during thyrotoxic phase; monitor TSH/FT4 every 2–4 weeks because most transition rapidly to permanent hypothyroidism (check morning cortisol before starting LT4 if hypophysitis is possible → immune checkpoint inhibitor toxicity).
amiodarone-induced thyrotoxicosis (AIT)
| feature | Type 1 AIT (Jod–Basedow) | Type 2 AIT (destructive thyroiditis) |
|---|---|---|
| mechanism | excess iodine synthesis (underlying Graves or nodular goitre) | direct follicular cell toxicity (normal gland) |
| colour-flow Doppler US | ↑ vascularity (often unreliable alone) | absent / ↓ vascularity |
| first-line therapy | methimazole (often high dose, 30–40 mg/day) | prednisone (e.g. 30–40 mg/day with taper) |
- Unstable or uncertain subtype (frequent overlap): start both methimazole and prednisone together (ATA 2016 strong recommendation).
- Stopping amiodarone: decide jointly with cardiology — its tissue half-life lasts months and abrupt withdrawal removes cardiac T3 antagonism, risking fatal arrhythmias.
Graves orbitopathy (EUGOGO 2021)
Assess activity (Clinical Activity Score CAS ≥3/7 = active: retrobulbar pain, gaze pain, lid/conjunctival redness, lid/caruncle swelling, chemosis) and severity (mild, moderate–severe, sight-threatening).
- All patients: strict smoking cessation (strongest modifiable risk factor for progression and poor treatment response), restore euthyroidism promptly, avoid post-RAI hypothyroidism, and start preservative-free lubricating eye drops/gels.
- Mild active GO: local lubricants + selenium (sodium selenite 200 µg daily × 6 months); avoid RAI or cover with prednisone.
- Moderate–severe active GO: first-line = IV methylprednisolone (cumulative 4.5 g over 12 weekly infusions) + mycophenolate (sodium 720 mg/day or MMF 1 g/day × 24 weeks); for more severe cases (constant/inconstant diplopia, severe proptosis/soft-tissue signs), use higher-dose IV methylprednisolone 7.5 g monotherapy (cumulative safety limit 8.0 g/cycle — not combined with mycophenolate). Second-line options: repeat IV steroids, orbital radiotherapy, rituximab, tocilizumab, or teprotumumab (availability in Canada limited).
- Sight-threatening GO (dysthyroid optic neuropathy or corneal breakdown): urgent high-dose IV methylprednisolone (500–1,000 mg daily × 3 days or alternate days) → urgent orbital decompression if poor response within 1–2 weeks.
- Rehabilitative surgery (decompression → strabismus → eyelid): only once inactive for ≥6 months.
Prepared 2026-11-19. Not yet verified — check every number against the sources.